Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: A 12-months follow-up study

Ruiz‐Litago, Fátima; Seco, Jesús; Echevarrı́a, Enrique; Martínez‐Cengotitabengoa, Mónica; Gil, Javier; Irazusta, Jon; González‐Pinto, Ana

doi:10.1016/j.psychres.2012.07.024

Cited by 36 publications

(22 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Possible explanations for these differences are variations in medication use, especially in the proportion of the sample that was under clozapine use (Pedrini et al, 2012), and presence of psychiatric comorbidities (Noto et al, 2011). A similar rationale has been described for oxidative stress (Gama et al, 2008), where treatment with atypical antipsychotics was associated with reduction of oxidative stress, including TBARS levels (Dietrich-Muszalska et al, 2011;Ruiz-Litago et al, 2012).…”

Section: Discussionmentioning

confidence: 91%

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia

Asevedo

Gadelha

Noto

et al. 2013

Journal of Psychiatric Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia

Asevedo

Gadelha

Noto

et al. 2013

Journal of Psychiatric Research

View full text Add to dashboard Cite

“…Psychotic patients in general are in a significantly increased longterm con dition of oxidative stress [102,103] . Oxidative stress markers, such as pentosidine [104] , glycer-AGE [105] and thiobarbituric acid reactive substances [103,106] were found to be higher among people with Sz and carbonyl stress was found to be lower in people with the disorder [104,105,107] . However, those oxidative markers have overlapping levels between people with Sz and healthy individuals, suggesting the discriminability of those markers is low [102] .…”

Section: Metabolismmentioning

confidence: 99%

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Lai

Scarr

Udawela

et al. 2016

WJP

137

108

View full text Add to dashboard Cite

Identifying biomarkers that can be used as diagnostics or predictors of treatment response (theranostics) in people with schizophrenia (Sz) will be an important step towards being able to provide personalized treatment. Findings from the studies in brain tissue have not yet been translated into biomarkers that are practical in clinical use because brain biopsies are not acceptable and neuroimaging techniques are expensive and the results are inconclusive. Thus, in recent years, there has been search for blood-based biomarkers for Sz as a valid alternative. Although there are some encouraging preliminary data to support the notion of peripheral biomarkers for Sz, it must be acknowledged that Sz is a complex and heterogeneous disorder which needs to be further dissected into subtype using biological based and clinical markers. The scope of this review is to critically examine published blood-based biomarker of Sz, focusing on possible uses for diagnosis, treatment response, or their relationship with schizophreniaassociated phenotype. We sorted the studies into six categories which include: (1) brain-derived neurotrophic factor; (2) inflammation and immune function; (3) neurochemistry; (4) oxidative stress response and metabolism; (5) epigenetics and microRNA; and (6) transcriptome and proteome studies. This review also summarized the molecules which have been conclusively reported as potential blood-based biomarkers for Sz in different blood cell types. Finally, we further discusses the pitfall of current blood-based studies and suggest that a prediction model-based, Sz specific, blood World Journal of Psychiatry W J P oriented study design as well as standardize blood collection conditions would be useful for Sz biomarker development.

show abstract

“…The behavioral and physiological characteristics of the disease can be mimicked by drugs that cause dopamine overproduction or block NMDA receptors. Oxidative stress increases in schizophrenia as evidenced by reports of changes in oxidative stress biomarkers such as increased oxidized-to-reduced glutathione ratios in the blood of patients (48,233,245) and decreased reduced glutathione levels in cerebrospinal fluid and postmortem prefrontal cortices of schizophrenic patients (63). Limited studies have also reported amelioration of symptoms after treatment of patients with the antioxidant N-acetyl cysteine (21,33).…”

Section: Diebold Et Almentioning

confidence: 99%

NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress

Diebold

Smith

Yang

et al. 2015

Antioxidants & Redox Signaling

106

View full text Add to dashboard Cite

Significance: NOX2 is important for host defense, and yet is implicated in a large number of diseases in which inflammation plays a role in pathogenesis. These include acute and chronic lung inflammatory diseases, stroke, traumatic brain injury, and neurodegenerative diseases, including Alzheimer's and Parkinson's Diseases. Recent Advances: Recent drug development programs have targeted several NOX isoforms that are implicated in a variety of diseases. The focus has been primarily on NOX4 and NOX1 rather than on NOX2, due, in part, to concerns about possible immunosuppressive side effects. Nevertheless, NOX2 clearly contributes to the pathogenesis of many inflammatory diseases, and its inhibition is predicted to provide a novel therapeutic approach. Critical Issues: Possible side effects that might arise from targeting NOX2 are discussed, including the possibility that such inhibition will contribute to increased infections and/or autoimmune disorders. The state of the field with regard to existing NOX2 inhibitors and targeted development of novel inhibitors is also summarized. Future Directions: NOX2 inhibitors show particular promise for the treatment of inflammatory diseases, both acute and chronic. Theoretical side effects include pro-inflammatory and autoimmune complications and should be considered in any therapeutic program, but in our opinion, available data do not indicate that they are sufficiently likely to eliminate NOX2 as a drug target, particularly when weighed against the seriousness of many NOX2-related indications. Model studies demonstrating efficacy with minimal side effects are needed to encourage future development of NOX2 inhibitors as therapeutic agents. Antioxid. Redox Signal. 23,

show abstract

Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: A 12-months follow-up study

Cited by 36 publications

References 24 publications

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress

Contact Info

Product

Resources

About